Vancomycin plus Gentamicin plus Rifampin — Competitive Intelligence Brief

Vancomycin plus Gentamicin plus Rifampin (Vancomycin plus Gentamicin plus Rifampin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination. Area: Infectious Disease.

marketed Antibiotic combination Bacterial cell wall (vancomycin), 30S ribosome (gentamicin), bacterial RNA polymerase (rifampin) Infectious Disease Small molecule

Target snapshot

Vancomycin plus Gentamicin plus Rifampin (Vancomycin plus Gentamicin plus Rifampin) — Michael E. DeBakey VA Medical Center. This triple-antibiotic combination kills bacteria through three complementary mechanisms: vancomycin and gentamicin inhibit protein synthesis and cell wall integrity, while rifampin inhibits bacterial RNA polymerase.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vancomycin plus Gentamicin plus Rifampin TARGET	Vancomycin plus Gentamicin plus Rifampin	Michael E. DeBakey VA Medical Center	marketed	Antibiotic combination	Bacterial cell wall (vancomycin), 30S ribosome (gentamicin), bacterial RNA polymerase (rifampin)
Dapsone plus Adapalene	Dapsone plus Adapalene	Allergan	marketed	Retinoid plus sulfone antibiotic combination	Retinoic acid receptors (adapalene); dihydrofolate reductase inhibition and neutrophil suppression (dapsone)
Acnatac® Gel right face	Acnatac® Gel right face	GWT-TUD GmbH	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Antibiotics, cefuroxime and metronidazole	Antibiotics, cefuroxime and metronidazole	Helsinki University Central Hospital	marketed	Beta-lactam antibiotic + nitroimidazole antibiotic combination	Bacterial penicillin-binding proteins (cefuroxime); anaerobic bacterial DNA (metronidazole)
Azithromycin + Metronidazole	Azithromycin + Metronidazole	Sheikh Zayed Medical College	marketed	Macrolide antibiotic + Nitroimidazole antibiotic combination	Bacterial 50S ribosome (azithromycin); anaerobic bacterial DNA (metronidazole)
Acnatac® Gel left face	Acnatac® Gel left face	GWT-TUD GmbH	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide)
BENZOYL PEROXIDE/ CLINDAMYCIN	BENZOYL PEROXIDE/ CLINDAMYCIN	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination class)

1. Michael E. DeBakey VA Medical Center · 2 drugs in this class
2. University of South Florida · 2 drugs in this class
3. Halmstad County Hospital · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Hospital de Clinicas de Porto Alegre · 1 drug in this class
6. McMaster University · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. The Cleveland Clinic · 1 drug in this class
10. The Forsyth Institute · 1 drug in this class